A 28-day study of the effect of Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 suture with triclosan) on wound healing in guinea pig linear incisional skin wounds.
BACKGROUND
This study evaluated the effect of coated polyglactin 910 suture with triclosan on tissue response and wound healing over a 28-day period on full-thickness linear wounds in the hairless guinea pig model.


METHODS
In situ wound strength was assessed, and histopathologic effects on tissue response and wound healing were evaluated. Four (1.9 cm) full-thickness incisional wounds were created on the dorsolateral region (two left and two right, approximately 3 cm apart) in 40 Hartley male hairless guinea pigs (400-500 g). A 1.9-cm segment of suture material was implanted "length-wise" into the incision and the sites closed with simple interrupted closure with 3-0 nylon sutures. The test material was 2-0 coated polyglactin 910 suture with triclosan and the control material was 2-0 Coated VICRYL* Suture (coated polyglactin 910 suture). On days 3, 7, 14, and 28 postimplantation (n = 10/time interval), body weights were recorded, tissue specimens harvested, and bursting strength testing performed.


RESULTS
There was no significant difference (P > 0.05) in bursting strength between the study groups for any of the time intervals studied. The bursting strengths (mm Hg) for the sutures with triclosan were 95.8 (day 3), 268.8 (day 7), 542.6 (day 14), and 633.8 (day 28). Both materials demonstrated comparable tissue response to implantation, and there were no significant differences (P > 0.05) observed in wound healing based on cellular response and collagen formation and orientation.


CONCLUSIONS
Based on the in vivo biomechanical testing and histological results, no evidence of impedance to wound healing was detected.
Storch
Mark
M
Ethicon, Inc, Somerville, New Jersey 08878, USA. mstorch@ethus.jnj.com
Perry
Larry C
LC
Davidson
Jeffrey M
JM
Ward
James J
JJ
D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage* / Q000494:pharmacology*; D001696:Biomechanical Phenomena; D020099:Coated Materials, Biocompatible / Q000494:pharmacology*; D004195:Disease Models, Animal; D006168:Guinea Pigs; D008297:Male; D011098:Polyglactin 910 / Q000494:pharmacology*; D013997:Time Factors; D015599:Trauma Severity Indices; D014260:Triclosan / Q000008:administration & dosage* / Q000494:pharmacology*; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology*; D014951:Wounds, Stab / Q000473:pathology* / Q000503:physiopathology*
D000891:Anti-Infective Agents, Local; D020099:Coated Materials, Biocompatible; D011098:Polyglactin 910; D014260:Triclosan